Suppr超能文献

2 级脑胶质瘤患者的无进展生存期与进展后生存期和总生存期比较。

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas.

机构信息

Department of Neurosurgery, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.

Clinical Research Unit, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

出版信息

Acta Oncol. 2024 Oct 20;63:798-804. doi: 10.2340/1651-226X.2024.40845.

Abstract

BACKGROUND AND PURPOSE

Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this subset of tumors is limited. We sought to assess correlations between PFS and OS, and identify factors associated with PFS, PPS, and OS in patients treated for diffuse supratentorial WHO grade 2 gliomas.

MATERIAL AND METHODS

We included 319 patients from three independent observational cohorts. The correlation between PFS and OS was analyzed using independent exponential distributions for PFS and time from progression to death. Cox proportional hazards models were used to determine the effects of covariates on PFS, PPS, and OS.

RESULTS

The overall correlation between PFS and OS was rs0.31. The correlation was rs 0.37 for astrocytomas and rs 0.19 for oligodendrogliomas. Longer PFS did not predict longer PPS. Patients with astrocytomas had shorter PFS, PPS, and OS. Larger preoperative tumor volume was a risk factor for shorter PFS, while older age was a risk factor for shorter PPS and OS. Patients who received early radio- and chemotherapy had longer PFS, but shorter PPS and OS.

INTERPRETATION

We found a weak correlation between PFS and OS in WHO grade 2 gliomas, with the weakest correlation observed in oligodendrogliomas. Our analyses did not demonstrate any association between PFS and PPS. Critically, predictors of PFS are not necessarily predictors of OS. There is a need for validation of PFS as an endpoint in diffuse WHO grade 2 gliomas.

摘要

背景与目的

无进展生存期(PFS)仍然需要在弥漫性世界卫生组织(WHO)2 级胶质瘤中得到验证,并且对于该肿瘤亚组中 PFS、进展后生存期(PPS)和总生存期(OS)之间的关系知之甚少。我们旨在评估 PFS 与 OS 之间的相关性,并确定与弥漫性幕上 WHO 2 级胶质瘤患者的 PFS、PPS 和 OS 相关的因素。

材料与方法

我们纳入了来自三个独立观察队列的 319 名患者。使用独立的 PFS 和从进展到死亡的时间的指数分布来分析 PFS 和 OS 之间的相关性。Cox 比例风险模型用于确定协变量对 PFS、PPS 和 OS 的影响。

结果

PFS 和 OS 之间的总体相关性为 rs0.31。星形细胞瘤的相关性为 rs0.37,少突胶质细胞瘤的相关性为 rs0.19。较长的 PFS 并不能预测较长的 PPS。星形细胞瘤患者的 PFS、PPS 和 OS 较短。术前肿瘤体积较大是 PFS 缩短的危险因素,而年龄较大是 PPS 和 OS 缩短的危险因素。接受早期放化疗的患者 PFS 较长,但 PPS 和 OS 较短。

结论

我们发现 WHO 2 级胶质瘤中 PFS 和 OS 之间存在弱相关性,其中少突胶质细胞瘤的相关性最弱。我们的分析并未显示 PFS 与 PPS 之间存在任何关联。重要的是,PFS 的预测因素不一定是 OS 的预测因素。需要对 PFS 在弥漫性 WHO 2 级胶质瘤中作为终点进行验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3ff/11500610/295c64793c42/AO-63-40845-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验